Comparison of therapeutic effect of sertraline and supportive psychotherapy in comparison with placebo in coronary heart disease patients with mild to moderate depression

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171105037241N2

Enrollment

Registered

2017-12-26

Start date

2017-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Mild Depression. Condition 3: Moderate depression. F32 Depressive episode In typical mild, moderate, or severe depressive episodes, the patient suffers from lowering of mood, reduction of energy, and decrease in activity. Capacity for enjoyment, interest, and concentration is reduced, and marked tire F32.0 Mild depressive episode Two or three of the above symptoms are usually present. The patient is usually distressed by these but will probably b

Interventions

Intervention 1: Intervention group: In this group, cognitive-behavioral interventions are performed to improve depression in patients with coronary artery disease. These interventions will be conducte

b) engaging in at least one meaningful activity for the patient for at least 15-20 minutes per day.Patients undergoing treatment are more likely to find a better chance to

Behavior

Treatment - Drugs

Placebo

Intervention group: In this group, cognitive-behavioral interventions are performed to improve depression in patients with coronary artery disease. These interventions will be conducted in seven sessi

Intervention group :Sertraline receiving group: In this group, sertraline tablets are given to patients 50 mg orally once a day and will receive 150 to 200 mg per week.

Control groupIn : the placebo group, the sertraline placebo will also be used, which is used in this study of vitamin C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: coronary heart disease mild to moderate depression No serious medical illness Non-use of psychiatric drugs

Exclusion criteria

Exclusion criteria: Heart medications affecting the mood

Design outcomes

Primary

Measure	Time frame
Depression level in patients with coronary artery disease. Timepoint: first, third, sixth weeks. Method of measurement: Hamilton Depression Survey Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadislam Sourizahi

Zahedan University of Medical Sciences

dr.sourizahi58@zaums.ac.ir+98 54 3329 5715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026